AUPH
Aurinia Pharmaceuticals Inc
$16.65
-3.59%
2026-08-21
About Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. It also develops aritinercept, a dual inhibitor of B cell-activating factor and proliferation-inducing ligand for the potential treatment of autoimmune diseases. The company was founded in 1993 and is headquartered in Edmonton, Canada.
Key Fundamentals
P/E Ratio
6.79
Forward P/E
14.50
EPS (TTM)
$2.28
ROE
66.1%
Revenue Growth (YoY)
18.9%
Profit Margin
100.8%
Debt/Equity
10.43
Price/Book
3.34
Beta
1.40
Market Cap
$2.06B
Avg Volume (10D)
1.2M
Recent Breakout Signals
Recent Price Range (60 Days)
60D High
$19.25
60D Low
$14.36
Avg Volume
1.5M
Latest Close
$16.65
Get breakout alerts for AUPH
Sign up for Breakout Scanner to receive daily notifications when AUPH triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial.
Aurinia Pharmaceuticals Inc (AUPH) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors AUPH daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. AUPH operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.